Based on the press release, Beckley Psytech Limited has reported its consolidated financial statements for the years ended December 31, 2024, 2023, and 2022. Here are the key figures from the press release:
Consolidated Statement of Comprehensive Loss: The operating loss for the year ended December 31, 2024, was £35,923, compared to an operating loss of £14,546 for the year ended December 31, 2023. The loss for the year ended December 31, 2024, was £22,469, while the loss for the year ended December 31, 2023, was £6,002.
Consolidated Statement of Financial Position: Total assets as of December 31, 2024, amounted to £76,223, compared to £71,906 as of December 31, 2023. Total liabilities as of December 31, 2024, were £17,190, while the total liabilities as of December 31, 2023, were £15,650. * The net assets as of December 31, 2024, stood at £59,033, compared to £56,256 as of December 31, 2023.
Consolidated Statement of Changes in Equity: The share capital as of December 31, 2024, was £10, compared to £8 as of December 31, 2023. The share premium as of December 31, 2024, was £95,656, while it was £75,569 as of December 31, 2023.
Consolidated Statement of Cash Flows: The loss before income taxes for the year ended December 31, 2024, was £30,853, compared to a loss of £14,068 for the year ended December 31, 2023. The share-based payment charge for the year ended December 31, 2024, amounted to £1,337, while it was £1,891 for the year ended December 31, 2023.
These figures indicate a significant increase in operating loss and net loss for the year ended December 31, 2024, compared to the previous year. Additionally, total assets, liabilities, and net assets have also increased from the prior year. Today the company's shares have moved -3.49% to a price of $5.26. For the full picture, make sure to review ATAI Life Sciences's 8-K report.
